Oculis raises USD 100 Million in oversubscribed share offering

14.02.2025 16:15, Rita Longobardi

Oculis, a global biopharmaceutical company focused on ophthalmic and neuro-ophthalmic diseases, has priced an underwritten offering of 5 million ordinary shares at USD 20.00 per share, raising USD 100 million. The proceeds will support the clinical development of its neuroprotective candidate Privosegtor (OCS-05) and pipeline advancements.

Oculis, a biopharmaceutical company focused on treatments for ophthalmic and neuro-ophthalmic diseases, has announced a successful underwritten offering of 5 million ordinary shares at USD 20.00 per share, generating gross proceeds of USD 100 million. The transaction is expected to close on or around February 18, 2025, pending customary closing conditions.

The offering was oversubscribed, reflecting strong investor interest. The new shares will be issued from Oculis' existing capital band, increasing the total number of authorized registered shares to 53,943,700, as outlined in the company’s Articles of Association.

Oculis plans to use the funds to advance its clinical development programs, with a particular focus on Privosegtor (OCS-05), a novel neuroprotective candidate. Additional proceeds will support working capital and general corporate initiatives.

BofA Securities—the investment banking division of Bank of America—and Leerink Partners are serving as joint book-running managers, with Pareto Securities acting as lead manager and Arctica Finance as financial advisor.

The offering is being conducted under a registration statement on Form F-3, a streamlined filing used by foreign private issuers to register securities in the US. The form allows companies that meet SEC (Securities and Exchange Commission) reporting requirements to raise capital efficiently. Oculis filed its Form F-3 with the US SEC on April 1, 2024, and it was declared effective on April 3, 2024.

Oculis was ranked among the TOP 100 Swiss Startups in 2020 and 2022.


Riad Sherif (CEO), Gudrun Bachmann (CTO), Daniel S. Char (Chief Legal Officer), and Sylvia Cheung (CFO)